Papulosquamous Disorders Flashcards
Pityriasis Rosea
A benign common rash seen in otherwise healthy people
● Name means: “fine, pink scale”
● Acute, self-limiting papulosquamous eruption
Pityriasis Rosea pathophysiology
● Considered a viral exanthem
o Increased CD4 T cells and Langerhans
cells are present in dermis
● Has been linked to URIs
● Most often occurs in spring and winter
● Does not appear to be highly contagious;
no need to isolate
Pityriasis Rosea etiology
● May result from infections, medications, immunizations
Medication Causes
● Omeprazole, terbinafine, captopril,
isotretinoin, psychotropic medication,
etc
Vaccine Causes
● Smallpox, TB, flu, Tdap, yellow fever, COVID-19
(Moderna and others)
Pityriasis Rosea presentation
● In 50-90% of cases, the primary/
“herald” plaque is seen a week or more
before the smaller lesions erupt
o Initial plaque is often salmon
colored and oval and on the back
● Pruritus may be present (25-75%)
● The smaller lesions follow the lines of
cleavage of the skin on back and
abdomen mostly
o Christmas Tree Pattern
Pityriasis Rosea diagnosis
● Clinical
● Lab tests not typically needed
Pityriasis Rosea treatment
● Supportive – spontaneous resolution in
about 6 weeks
● UV radiation therapy
● Pruritus – zinc oxide, calamine lotion,
antihistamine, etc.
● If severe, topical or oral steroids
Psoriasis
● Psoriasis is a complex, chronic,
multifactorial, inflammatory
disease
● Involves hyperproliferation of the
keratinocytes in the epidermis
● An increased epidermal cell
turnover rate
● Environmental, genetic, and
immunologic factors play a role
● Has remissions and exacerbations
Psoriasis etiology
● Patients typically have a genetic
predisposition
● Commonly affects the elbows, knees,
scalp, lumbosacral areas, intergluteal
clefts, and glans penis
● Joints are affected in 30% of patients
● Is likely an autoimmune condition
o NOT CONTAGIOUS
Psoriasis pathophysiology
● Not completely understood
● No obvious trigger in many patients
● Once triggered, leukocytes are
recruited to the dermis and epidermis → psoriatic plaques
● Large numbers of activated T
cells → keratinocyte proliferation
● T-cell hyperactivity and proinflammatory mediators play a large role in the pathogenesis of psoriasis
● Low levels of lipids and cells with retained nuclei lead to a poorly adherent stratum
corneum → flaking, scaly lesions
Psoriasis key findings
o Vascular engorgement due to superficial blood vessel dilation
o Altered epidermal cell cycle → improper cell
maturation
Psoriasis etiology
Environmental Factors
● Stress
● Cold
● Trauma
● Infections (Strep)
● Alcohol
● Medications
Genetic Factors
● 40% of individuals with
psoriasis have a family history
of psoriasis
Other Factors
● Obesity
● Smoking
● Low Vitamin D levels
Psoriasis epidemiology
● Approximately 2-3.6% of the
US population has psoriasis
● Bimodal peak in ages: 20-30
years and 50-60 years
● Slightly more prevalent in
women
Psoriasis presentation
o Scaling, salmon-colored/ erythematous
macules, papules, and plaques
○ Macules are noted first and progress to
maculopapules and then
well-demarcated, silvery plaques
overlying glossy erythema
Ocular manifestations of psoriasis
○ May appear as conjunctivitis,
corneal dryness, etc.
○ Blepharitis is the most common
ocular finding
Psoriasis diagnosis
● Clinical
● If difficult to identify, consider
biopsy
● Auspitz sign = pinpoint drops
of blood appear after scales
are removed
● Can differentiate psoriatic
arthritis from RA and gout by
absence of lab findings
Psoriasis treatment
● Those with mild skin disease can often be managed with topical therapies
● Moderate to severe disease typically requires phototherapy or systemic
agents
Psoriasis treatment for mild disease
o Daily sun exposure, sea bathing, topical
moisturizers, and relaxation
● Daily moisturizing (eg. petroleum jelly)
● Limited lesions respond well to
o Topical corticosteroids
o Emollients
o Vitamin D analogs (eg. calcitriol)
o Coal tar
o Topical retinoids
Psoriasis treatment for mod-severe lesions
o Retinoids
o Methotrexate
o Cyclosporine
o Biologics (eg. adalimumab)